Cytosorbents Crp

Yahoo Finance • 2 months ago

Notable ETF Outflow Detected - GSLC, VRSN, IDXX, FAST

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Goldman Sachs ActiveBeta U.S. Large Cap Equity ETF (Symbol: GSLC) where we have detected an approximate $164.... Full story

Yahoo Finance • 2 months ago

Wednesday's pre-market session: top gainers and losers

Before the US market kicks off on Wednesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. [premarket] PRE-MARKET GAINERS TICKER CHANGE COMMENT NBY [https://www.chart... Full story

Yahoo Finance • 2 months ago

Cytosorbents outlines DrugSorb ATR regulatory appeals and targets core business breakeven as German reorganization drives 22% sales growth

Earnings Call Insights: Cytosorbents Corporation (CTSO) Q2 2025 MANAGEMENT VIEW * CEO Phillip P. Chan introduced Cytosorbents as a leader in blood purification for critical care and cardiac surgery, emphasizing that CytoSorb, the flags... Full story

Yahoo Finance • 3 months ago

Cytosorbents stock plunges after regulatory setbacks for key device

Investing.com -- Cytosorbents Corporation (NASDAQ:CTSO) stock plunged 23.5% after the blood purification therapy company received regulatory rejections for its DrugSorb-ATR device from both the U.S. FDA and Health Canada. The company disc... Full story

Yahoo Finance • 3 months ago

CytoSorbents receives FDA appeal hearing date for DrugSorb-ATR device

PRINCETON, N.J. - CytoSorbents Corporation (NASDAQ:CTSO), a medical device company with a market capitalization of $81 million and impressive YTD returns of 42%, announced today that the U.S. Food and Drug Administration has scheduled an a... Full story

Yahoo Finance • 4 months ago

CytoSorbents files appeal with FDA over denied device application

PRINCETON, N.J. - CytoSorbents Corporation (NASDAQ:CTSO), a $79 million market cap medical device company with a 15% year-over-year revenue growth, filed a request for supervisory review with the U.S. Food and Drug Administration on June 1... Full story

Yahoo Finance • 4 months ago

CytoSorbents Q1 2025 slides: Revenue dips 3% as company targets breakeven by year-end

Introduction & Market Context CytoSorbents Corporation (NASDAQ:CTSO) presented its first quarter 2025 financial results on May 14, highlighting mixed performance as the blood purification technology company continues its push toward opera... Full story

Yahoo Finance • 7 months ago

CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller

PRINCETON, N.J., March 04, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announce... Full story

Yahoo Finance • 2 years ago

Cytosorbents Corporation (NASDAQ:CTSO) Q3 2023 Earnings Call Transcript

Cytosorbents Corporation (NASDAQ:CTSO) Q3 2023 Earnings Call Transcript November 9, 2023 Cytosorbents Corporation misses on earnings expectations. Reported EPS is $-0.20718 EPS, expectations were $-0.12. Operator: Good afternoon, and wel... Full story

Yahoo Finance • 2 years ago

CytoSorbents Reports Third Quarter 2023 Financial and Operational Results

PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its propriet... Full story

Yahoo Finance • 2 years ago

CytoSorbents to Report Third Quarter 2023 Operating and Financial Results

PRINCETON, N.J., Oct. 27, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report thi... Full story

Yahoo Finance • 2 years ago

CytoSorbents to Present at the 8th Annual Dawson James Conference

PRINCETON, N.J., Oct. 05, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that... Full story

Yahoo Finance • 2 years ago

CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry

PRINCETON, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary poly... Full story

Yahoo Finance • 2 years ago

CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer

PRINCETON, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in cr... Full story

Yahoo Finance • 2 years ago

CytoSorbents Announces Resignation of Chief Financial Officer Alexander D’Amico

PRINCETON, N.J., Sept. 01, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary poly... Full story

Yahoo Finance • 2 years ago

CytoSorbents And Humedics Announce Theranostic Collaboration in the Field of Liver Disease

PRINCETON, N.J., July 11, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its propriet... Full story

Yahoo Finance • 2 years ago

CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial

PRINCETON, N.J., July 07, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polym... Full story

Yahoo Finance • 2 years ago

CytoSorbents Announces Independent Data Safety and Monitoring Board Recommends Completion of the Pivotal STAR-T Trial Without Modifications Following Second Scheduled Safety Review

PRINCETON, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its propriet... Full story

Yahoo Finance • 2 years ago

Cytosorbents Corporation (NASDAQ:CTSO): Is Breakeven Near?

With the business potentially at an important milestone, we thought we'd take a closer look at Cytosorbents Corporation's (NASDAQ:CTSO) future prospects. Cytosorbents Corporation engages in the research, development, and commercialization... Full story

Yahoo Finance • 2 years ago

CytoSorbents to Report First Quarter 2023 Operating and Financial Results

MONMOUTH JUNCTION, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will r... Full story